Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Therapeutic Potential of … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Therapeutic Potential of Sc-47 in Comparison to Lu-177 and Y-90: Preclinical Investigations

Artikel i vetenskaplig tidskrift
Författare K. Siwowska
P. Guzik
K. A. Domnanich
J. M. M. Rodriguez
Peter Bernhardt
B. Ponsard
R. Hasler
F. Borgna
R. Schibli
U. Koster
N. P. van der Meulen
C. Muller
Publicerad i Pharmaceutics
Volym 11
Nummer/häfte 8
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för radiofysik
Språk en
Länkar dx.doi.org/10.3390/pharmaceutics110...
Ämnesord Sc-47, Lu-177, Y-90, radionuclide therapy, SPECT, folate receptor, DOTA-folate, IGROV-1 tumor, receptor radionuclide therapy, tumor-therapy, in-vitro, vivo, y-90-dotatoc, toxicity, growth, beta, Pharmacology & Pharmacy
Ämneskategorier Radiologi och bildbehandling

Sammanfattning

Targeted radionuclide therapy with Lu-177- and Y-90-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. Sc-47 is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy beta(-)particles. In this study, Sc-47 was investigated, in combination with a DOTA-folate conjugate, and compared to the therapeutic properties of Lu-17-folate and Y-90-folate, respectively. In vitro, Sc-47-folate demonstrated effective reduction of folate receptor-positive ovarian tumor cell viability similar to Lu-177-folate, but Y-90-folate was more potent at equal activities due to the higher energy of emitted beta(-)particles. Comparable tumor growth inhibition was observed in mice that obtained the same estimated absorbed tumor dose (similar to 21 Gy) when treated with Sc-47-folate (12.5 MBq), Lu-177-folate (10 MBq), and Y-90-folate (5 MBq), respectively. The treatment resulted in increased median survival of 39, 43, and 41 days, respectively, as compared to 26 days in untreated controls. There were no statistically significant differences among the therapeutic effects observed in treated groups. Histological assessment revealed no severe side effects two weeks after application of the radiofolates, even at double the activity used for therapy. Based on the decay properties and our results, Sc-47 is likely to be comparable to Lu-177 when employed for targeted radionuclide therapy. It may, therefore, have potential for clinical translation and be of particular interest in tandem with Sc-44 or Sc-43 as a diagnostic match, enabling the realization of radiotheragnostics in future.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?